Hemorrhagic transformation (HT) is a common complication of ischemic stroke that is exacerbated by thrombolytic therapy. Methods to better prevent, predict, and treat HT are needed. In this review, we summarize studies of HT in both animals and humans. We propose that early HT (o18 to 24 hours after stroke onset) relates to leukocyte-derived matrix metalloproteinase-9 (MMP-9) and brain-derived MMP-2 that damage the neurovascular unit and promote blood-brain barrier (BBB) disruption. This contrasts to delayed HT (418 to 24 hours after stroke) that relates to ischemia activation of brain proteases (MMP-2, MMP-3, MMP-9, and endogenous tissue plasminogen activator), neuroinflammation, and factors that promote vascular remodeling (vascular endothelial growth factor and high-moblity-group-box-1). Processes that mediate BBB repair and reduce HT risk are discussed, including transforming growth factor beta signaling in monocytes, Src kinase signaling, MMP inhibitors, and inhibitors of reactive oxygen species. Finally, clinical features associated with HT in patients with stroke are reviewed, including approaches to predict HT by clinical factors, brain imaging, and blood biomarkers. Though remarkable advances in our understanding of HT have been made, additional efforts are needed to translate these discoveries to the clinic and reduce the impact of HT on patients with ischemic stroke.
INTRODUCTION
Hemorrhagic transformation (HT) is bleeding into an area of ischemic brain after stroke. It occurs in as many as 10% to 40% of patients with ischemic stroke, 1,2 and is associated with increased stroke morbidity and mortality. [3] [4] [5] It is the major complication of tissue plasminogen activator (tPA), the only FDA-approved therapy for acute ischemic stroke. Thus, improved understanding of HT is essential to reduce its impact on patients with ischemic stroke and improve our ability to restore blood flow to ischemic brain without producing this complication.
The severity of HT can vary from microscopic bleeding to large hemorrhages. Clinical studies frequently divide HT into four groups: small petechial hemorrhagic infarction (HI1), confluent petechial hemorrhagic infarction (HI2), small parenchymal hemorrhage (PH1) (o30% of infarct, mild mass effect), and large parenchymal hemorrhage (PH2, 430% of infarct, marked mass effect). 3 Hemorrhagic transformation is also often divided into symptomatic or asymptomatic groups based on the deterioration in neurologic status, defined as an increase in the National Institutes of Health Stroke Scale by 44 points within the first 36 hours of stroke onset. 6 These clinical classifications are useful in that larger hemorrhages are more likely symptomatic, more likely to negatively affect stroke outcomes, and thus are important to prevent. 3, 5, 7, 8 However, even so-called 'asymptomatic' HT can worsen stroke outcomes, particularly when cognition and neurologic function are assessed weeks to months after stroke onset. 6, 9 This may relate in part to exacerbation of cerebral edema and other toxic effects of blood produced by HT. 10 Thus, reducing smaller HT may also benefit patients with stroke.
Hemorrhagic transformation occurs when cerebral blood flow is restored to damaged vasculature. There remains some uncertainty as to whether the mechanisms that cause smaller petechial hemorrhages are the same as larger parenchymal hemorrhages. Some have argued that they differ since petechial hemorrhage relates to the duration and severity of ischemia, whereas parenchymal hemorrhage may not. 11 In addition, petechial hemorrhage is often thought to be a marker of good outcome, possibly because it indicates early reperfusion to still viable brain tissue. Nonetheless, in either petechial or parenchymal hemorrhage the cause of bleeding is injury to and/or remodeling of blood vessels which form the blood-brain barrier (BBB) and are part of the neurovascular unit (vessel-glianeuron). 12 In the following sections, we summarize the factors that contribute to HT in animals and humans. We highlight that reperfusion alone without tPA is a key factor to generate HT. However, when tPA is administered the risk of HT is increased through a number of discussed mechanisms. We present evidence suggesting that there is a difference between HT that occurs early after stroke compared with HT that is delayed.
The key roles of reactive oxygen species (ROS), metalloproteinases, and other proteases are discussed, including the relationship between leukocyte-derived and brain-derived factors. We summarize potential methods to restore BBB integrity after stroke and reduce HT. Finally, we discuss the clinical factors and predictors that have been associated with HT.
HEMORRHAGIC TRANSFORMATION AND REPERFUSION WITHOUT TISSUE PLASMINOGEN ACTIVATOR
Many animal studies have focused on HT related to tPA. From a mechanistic point of view, this complicates interpretation of results as the effects of brain ischemia and reperfusion are difficult to separate from the effects of tPA. To address the effects of reperfusion alone, we compared permanent and temporary mechanical cerebral artery occlusions without tPA. 13 In rats, the rate of HT can be increased by increasing the duration of time from stroke onset to reperfusion of ischemic tissue. For example, in Sprague Dawley rats with a middle cerebral artery occlusion (MCAO), reperfusion at 5 hours results in 81.8% of rats having HT. In contrast, with permanent MCAO the rate of HT is only 18.2% (Po0.05). Mortality rates are also increased in the group reperfused at 5 hours (54.5%) compared with the permanent MCAO group (18.1%) . Thus, delayed reperfusion after prolonged ischemia increases the rate of HT and worsens stroke outcome. 13, 14 These rodent studies are consistent with ischemic stroke in humans where reperfusion by mechanical means increases the risk of HT. 15 There is a strong relationship between duration of ischemia and reperfusion induced HT. In rats, duration of ischemia increases the rate of HT increase ( Figure 1A ). In Wistar rats MCAO lasting 1.5, 2.5, 3.5, and 5 hours the rate of HT at 24 hours after stroke is 25%, 50%, 75%, and 100%, respectively. 16 Similar rates of HT have been observed in mice and Sprague Dawley rats in both the MCAO and clot injection stroke models. 13, 17, 18 If reperfusion does not occur, then the risk of HT is lower (18.2%) ( Figure 1B ). 13, 14 In humans, increased time from ischemia onset to reperfusion has also been associated with an increase in HT risk in both tPA-treated anduntreated patients. 17 Recanalization that occurs beyond 46 hours of stroke onset is an independent predictor of HT in human stroke. 19 In contrast, early reperfusion is associated with a reduced risk of HT. 20 Thus, time from stroke onset to reperfusion is a key factor in determining the rate of HT, with longer durations of ischemia increasing the likelihood of HT when blood flow is restored.
Though time to reperfusion is a key factor in determining the risk of HT in both animals and humans, other aspects important to HT in patients with stroke may not be reproduced in animal stroke models. 21 Patients often have multiple vascular risk factors and comorbid disease that are associated with HT but are not usually modeled in animals ( Table 1 ). In animal MCAO models, full reperfusion occurs rapidly as the suture is withdrawn. However in humans, reperfusion may be a more dynamic process that can occur gradually over hours with periods of partial reperfusion. The timing of HT after stroke onset and its relationship may also warrant consideration. Many of the animal models have evaluated HT that occurs within the first 24 hours of stroke onset. However, in patients with stroke the timing of HT can be quite variable, occurring within the first 24 hours in some 22 but also occurring at later time points several days after stroke. 23 Many of the symptomatic intracranial hemorrhages recorded in human tPA stroke trials have been noted within the first 24 to 36 hours of stroke onset. 8, [24] [25] [26] However, HT can occur as late as 1 week after stroke. 24, 27 Thus, several factors present in human stroke likely warrant consideration in animals to better model reperfusion and the complexity of HT that occurs in patients.
HEMORRHAGIC TRANSFORMATION AND TISSUE PLASMINOGEN ACTIVATOR
Hemorrhagic transformation is a major concern in patients treated with tPA. Tissue plasminogen activator increases the rate of HT by as much as 10-fold. 24, 28 Given that tPA remains the only FDAapproved medical therapy for acute ischemic stroke, methods to reduce HT in tPA-treated patients are of critical importance. An improved understanding of HT could aid in the prediction and/or prevention of tPA-related HT, thus improving its safety profile. Preventing tPA-related HT might make it possible to extend the therapeutic window and increase the eligibility criteria for thrombolysis. In addition, strategies to prevent tPA-related HT may also be applicable to other reperfusion strategies such as endovascular therapy.
Tissue plasminogen activator increases the risk of HT through a number of mechanisms. 29, 30 One reason is that tPA promotes reperfusion by degrading fibrin-based blood clots. As presented in the preceding section, reperfusion is a key factor in HT formation. However, tPA promotes HT through mechanisms beyond its role in thrombolysis and reperfusion. 31 It does this in part by increasing matrix metalloproteinase-9 (MMP-9), 32 MMP-2, 33 and MMP-3 34 and through effects mediated by specific receptors (Figure 2 ). Tissue plasminogen activator acts on the protease activated receptor 1 to increase the MMP-9 expression via NFkB. 35 It also binds the platelet-derived growth factor receptor alpha (PDGFRa) to activate PDGF-CC. 36 Of note, tPA binding to the PDGFRa on astrocyte end feet increases the BBB permeability 36 and increased levels of PDGF-CC are associated with HT in tPA-treated stroke patients 37 (Figure 2 ). Tissue plasminogen activator also binds the lipoprotein receptor protein (LRP) receptor on endothelial cells to increase MMP-3 and MMP-9 expression. 32, 34, 38 Finally, tPA can promote neutrophil degranulation and the release of MMP-9 into the blood. 39 Thus, in tPA-treated patients HT may occur not only as a result of increased reperfusion, but also through tPA's effects on metalloproteinase activity, PDGFRa and LRP receptor signaling. Middle cerebral artery occlusions (MCAOs) lasting 1 to 5.5 hours were induced in Wistar and Sprague Dawley (SD) rats. After reperfusion, the rate of HT was determined 24 hours after stroke onset. 13, 14, 16, 17 (B) The rate of HT as a function of MCAO duration. Increased duration of MCAO increases the rate of HT in several rat stroke models. Evaluation beyond 24 hours of stroke onset identifies additional HT in the spontaneously hypertensive rat (SHR). Note that a 0.5-hour MCAO in an SD rat does not produce HT at 24 hours, whereas a 0.5-hour MCAO in the SHR does produce HT with a 100% HT rate at 7 days after stroke onset.
EARLY AND DELAYED HEMORRHAGIC TRANSFORMATION
Disruption of the BBB is central to HT formation in ischemic stroke. After ischemic brain injury, disruption of the BBB occurs early. 40 Within 10 minutes of reperfusion, there is evidence of basal lamina degradation and BBB disruption. 41, 42 In humans, early opening of the BBB has been documented within 2 to 6 hours (median 3.8 hours) of stroke onset. 21, 43 The early disruption of the BBB in stroke may not be uniform over time. Indeed, periods of enhanced early BBB permeability have been observed at 4 to 8 hours and again at 12 to 16 hours. 44, 45 These escalations in early BBB opening may relate to aspects of an evolving infarct and perfusion status such as hyperemia and hypoperfusion. 45 Beginning at B24 hours, a persistent disruption of the BBB is present that lasts for weeks.
In this review, we suggest the possibility of two types of HT, an early HT that occurs within the first 18 to 24 hours of stroke onset and a delayed HT that occurs after 18 to 24 hours of stroke onset. We propose that the mechanisms contributing to early BBB disruption and early HT differ from those involved in delayed BBB disruption and delayed HT ( Figure 3 ). In early HT, ROS, bloodderived MMP-9, and brain-derived MMP-2 have emerged as Stroke severity/NIHSS 50, 143, 144, [146] [147] [148] 170 Systolic blood pressure 144, 146, 152, 153 Hypertension history 144, 145 Glucose 50, 143, 144, 146, 148, 170 Diabetes 170 Body weight 144 Gender 146 Congestive heart failure 50, 148 Atrial fibrillation 50, 148 Renal impairment 50, 148 Antiplatelet use 8, 50, 144, [167] [168] [169] Platelet count 143 Anticoagulant/international normalized ratio/partial thromboplastin time 162 Time to reperfusion 144 Blood marker MMP-9 60 Activated protein C 183 Thrombin activatable fibrinolysis inhibitor (TAFI) 184 Plasminogen activator inhibitor-1 (PAI-1) 184 Vascular adhesion protein-1 (VAP-1) 185 Tight junction proteins: CLDN5, OCLN, ZO1 75 Platelet-derived growth factor-CC (PDGF-CC) 37 Genetics Leukocyte mRNA (AREG, MARCH7, SMAD4, INPP5D, MCFD2, VEGI) 76 a-2-macroglobulin 164 Factor XII 164 Factor XIII 165 Neuroimaging Infarct size/diffusion weighted imaging infarct volume 152, 186 Early infarct sign 50, 145, 170 Dense cerebral artery sign 145 Leukoaraiosis 50 MRI enhancement pattern 172 BBB permeability 174 HARM 173 Apparent diffusion coefficient value 176 Collateral flow 20 Cerebral blood flow or volume 177 Rating scores HAT (NIHSS, glucose, early infarct sign, diabetes) 170 Multicenter Stroke Survey (age, NIHSS, glucose, platelet count) 143 SITS-SICH (age, NIHSS, glucose, systolic BP, hypertension history, body weight, time to thrombolysis, antiplatelet) 144 SEDAN score (NIHSS, glucose, early infract sign, dense artery sign) 145 GRASPS score (age, NIHSS, glucose, systolic BP, sex, asian race) 146 SPAN-100 index (age, NIHSS) 147 iScore (age, NIHSS, glucose, sex, stroke subtype, atrial fibrillation, congestive heart failure, prior myocardial infarction, smoker, cancer, dialysis, prior disability) 148 MMP-9, matrix metalloproteinase-9; AREG, amphiregulin; MARCH7, membrane-associated ring finger (C3HC4) 7; SMAD4, SMAD family member 4; INPP5D, inositol polyphosphate-5-phosphatase; MCFD2, multiple coagulation factor deficiency 2; VEGI, vascular endothelial growth inhibitor; MRI, magnetic resonance imaging; BBB, blood-brain barrier; HARM, Hyperintense Acute Injury Marker; HAT, Hemorrhage After Thrombolysis; BP, blood pressure; SEDAN, blood Sugar, Early infarct signs and hyperDense cerebral artery sign, Age, and NIHSS; SITS-SICH, Safe Implementation of Thrombolysis in Stroke Symptomatic Intracerebral Hemorrhage; GRASPS, Glucose Race Age Sex Pressure Stroke Severity; SPAN, Stroke Prognostication using Age and NIHSS; NIHSS, National Institutes of Health Stroke Scale.
important mediators. In delayed HT, brain-derived factors including MMP-9, MMP-3, other proteases, vascular remodeling, and neuroinflammation begin to have a more prominent role. This is important as treatments designed to prevent HT may need to be tailored depending on the type of HT and causal factors. Evidence supporting this proposal is detailed below. Figure 2 . Diagram of cell types and molecules associated with hemorrhagic transformation (HT) after ischemic stroke. Neutrophils are a major source of MMP-9 within the first 18 to 24 hours of stroke onset, and brain is a major source of MMP-9 at 418 to 24 hours after stroke onset. Exogenous tPA can act on neutrophils to increase MMP-9. Endogenous tPA can act on endothelial cell lipoprotein receptor protein (LRP) to increase MMP-3, and on PDGF-CC to increase MMP-2 via astrocyte PDGFRa receptors. Monocytes bind CCR2, enter brain where TGFb1 induction of SMAD2 stabilizes the blood-brain barrier (BBB) and prevents HT for 1 to 7 days after stroke. AREG, amphiregulin; CCR2, C-C chemokine receptor type 2; EPC, endothelial progenitor cell; HMGB1, high-mobility-group-box-1; INPP5D, phosphatidylinositol-3,4,5trisphosphate 5-phosphatase 1; IRAK3, interleukin-1 receptor-associated kinase 3; MARCH7, membrane-associated ring finger (C3HC4) 7; MCFD2, multiple coagulation factor D2; MMP, matrix metalloproteinase; PDGF-CC, platelet-derived growth factor CC; PDGFRa, platelet-derived growth factor receptor alpha; ROS, reactive oxygen species; SMAD, mothers against decapentaplegic homolog; TGFb1, transforming growth factor b1; tPA, tissue plasminogen activator; VEGF, vascular endothelial growth factor; VEGI, vascular endothelial growth inhibitor. Figure 3 . Early reperfusion reduces the risk of hemorrhagic transformation (HT). Delayed reperfusion increases the BBB disruption and the risk of HT. ROS, leukocyte-derived MMP-9, and brain-derived MMP-2 have an important role in producing early BBB disruption and early HT. In contrast, brain-derived vascular remodeling, MMPs (MMP-9, MMP-2, and MMP-3), other brain proteases (plasmin, endogenous tPA, urokinase (uPA), and cathepsins), ROS, and neuroinflammation contribute to delayed BBB and delayed HT. A subset of monocytes that enter brain may prevent delayed HT. BBB, blood-brain barrier; MMP, matrix metalloproteinase; ROS, reactive oxygen species; SMAD, mothers against decapentaplegic homolog; TGFb1, transforming growth factor b1; tPA, tissue plasminogen activator; VEGF, vascular endothelial growth factor; HMGB1, high-mobility-group-box-1.
Early Hemorrhagic Transformation: Role of Reactive Oxygen Species Reactive oxygen species have an important role in early HT. Reperfusion of ischemic tissue results in the production of ROS from several sources, including intracellular mitochondria, nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), xanthine oxidases, cellular membrane receptors, and inflammatory mediators 29, 46 (Figure 3 ). Increased ROS produced by ischemia-reperfusion can disrupt the neurovascular unit through damage to endothelial cells, pericytes, smooth muscle cells, and astrocytes. This results in increased BBB permeability and increased likelihood of HT. Reactive oxygen species damage of the neurovascular unit at the capillary level might predispose to petechial hemorrhage, whereas at the small arteriolar level ROS injury to both endothelial and smooth muscle cells could produce larger parenchymal hemorrhages. Experimental evidence supports a role of ROS in early HT. Superoxide and peroxynitrite have been found to disrupt microvascular integrity and thus may contribute to HT. After 2 hours of MCAO and 3 hours of reperfusion in a rat, both superoxide and peroxynitrite are increased in microvessels and astrocytic end feet. 46 In this model, disruption of the BBB correlated with ROS levels, and was prevented by inhibiting nitric oxide. Levels of ROS are increased in reperfusion compared with permanent MCAO models. 44 In permanent MCAO, levels of ROS are lower, with an initial decrease that is followed by a slow rise over the course of 3 hours. In contrast, reperfusion after 1 hour of MCAO results in a burst in ROS formation and a sustained increase in levels over the course of 3 hours. The time course of reperfusion induced ROS over the first 24 hours has not been studied.
Superoxide radicals have also been shown to be an important mediator of early reperfusion induced BBB disruption. 30 In mice deficient in copper/zinc-superoxide dismutase (SOD1), ischemia induced BBB disruption was reduced by 88% (Po0.0001) after 3 hours of reperfusion and 73% (Po0.01) after 7 hours of reperfusion. Active in situ MMP mediated proteolysis was shown in ischemic leaking capillaries that produce ROS. 30 Superoxide in ischemic reperfusion may arise from xanthine oxidase or nicotinamide adenine dinucleotide phosphate oxidase (NOX2) in immune cells. 47 The rate of early HT and severity of BBB disruption are reduced in mice deficient in NOX2 and when NOX2 is inhibited. 47 In humans, the oxidative stress marker F2-isoprostane is increased in blood early after stroke onset (median 6 hours) 48 and plasma levels of 3-nitrotyrosine are elevated at 3 and 24 hours. 49 Indeed, several clinical factors associated with HT in stroke patients may promote the generation of ROS, including age, glucose, diabetes, infarct size, congestive heart failure, and renal impairment 50 ( Figure 3 ; Table 1 ). The association of ROS with ischemia-reperfusion injury and HT has led to several studies evaluating pharmacological inhibition of ROS production in stroke. In animals inhibiting ROS can decrease the BBB disruption and reduce the rate of HT. 51, 52 However, in humans inhibiting ROS was not found to reduce HT or improve stroke outcomes. 53 These studies are discussed in detail below in the section titled Treatment of Hemorrhagic Transformation.
Early Hemorrhagic Transformation: Role of Leukocyte/Neutrophil Metalloproteinases Ischemic stroke elicits a robust activation of the immune system. Within 30 minutes of focal cerebral ischemia, circulating leukocytes adhere to vascular endothelial cells. 45 By 6 hours, neutrophils have begun to enter the brain of rats with temporary MCAO. 54 Leukocyte adhesion and migration across the vasculature activates a number of signaling cascades (protein kinase C, focal adhesion kinase) that increase the BBB permeability. 45 Metalloproteinases including MMP-9, MMP-2, and MMP-3 are key molecules involved in BBB opening and HT after ischemic stroke. 40, 55, 56 Though the precise timing and cellular source of MMPs released after ischemia requires further study, circulating leukocytes are important contributors in early HT (Figures 2 and 3 ). Studies supporting this notion include the following:
(1) In rats and mice, plasma activity of MMP-9 and MMP-2 is increased within 3 to 8 hours of stroke onset. 13, 14, 55 Use of MMP inhibitors in these small animals decreases the BBB opening and the rate of HT. 13, 14 In primates, plasma MMP-9 activity is transiently increased within 2 hours of MCAO. 57 In humans, MMP-9 activity increases early, with a peak at 6 to 8 hours after stroke and a return toward baseline by 24 to 26 hours. 48 MMP-9 mRNA levels are also increased in human peripheral leukocytes at 3 and 5 hours after stroke with a return toward baseline by 24 hours 58, 59 (Figure 4 ). Thus, there appears to be a transient increase in MMP-9 levels in circulating leukocytes and plasma, with a peak between 2and 8 hours of ischemic stroke onset. Importanlty, MMP-9 plasma levels measured at 3 hours are predictive of subsequent HT [60] [61] [62] and early MMP-9 levels correlate with infarct severity and barrier injury. 63 This suggests that MMP-9 in the blood may contribute to early opening of the BBB and early HT (Figures 2 to 4 ). It is important to note some studies have found MMP-9 to be increased in the plasma beyond the 24-hour time point in ischemic stroke. 64 The reason for this increase in MMP-9 remains unclear, though it may relate to particular causes of stroke, comorbid disease, or size of infarct or a biphasic rise in MMP-9 with an initial early rise peaking by 6 to 8 hours followed by a second rise over the course of days. In addition, at least one study has suggested that neutrophils are not the primary source of MMP-9 involved in BBB disruption after stroke. 65 In this study, however, brain MMP-9 was measured at 24 and 72 hours which is beyond the early HT period where we postulate leukocytes are the major source of MMP-9. This is discussed in greater detail in the Delayed Hemorrhagic Transformation section below.
(2) Leukocytes are an important source of MMP-9 that contributes to early disruption of the BBB in ischemic stroke ( Figure 2 ). This suggestion is based on two mouse studies that specifically looked at blood-versus brain-derived MMP-9 in relationship to BBB breakdown. Gidday et al. 66 used MMP-9 knockout mice and chimeric knockouts lacking either MMP-9 in leukocytes or MMP-9 in resident brain cells. They found that early BBB breakdown is prevented in chimeric mice with leukocytes deficient in MMP-9. In fact, the reduction in BBB breakdown observed in the leukocyte MMP-9-deficient mouse was comparable to that observed in an MMP-9 knockout mouse. . Matrix metalloproteinase-9 (MMP-9) mRNA levels in blood of patients with ischemic stroke. MMP-9 mRNA was elevated at 3 and 5 hours after stroke compared with controls, with a return closer to baseline by 24 hours (*P ¼ 0.02; **P ¼ 9.9 Â 10 À 5 , ***P ¼ 8.6 Â 10 À 8 ).
However, in chimeric mice where leukocytes had intact MMP-9, breakdown of the BBB did occur. This indicates that MMP-9 from leukocytes (mainly neutrophils) mediates BBB breakdown early after stroke in this model. 66 These results were confirmed in an independent study by Wang et al. 67 Matrix metalloproteinase-9 null mice that received wildtype (MMP-9 intact) bone marrow had comparable levels of brain MMP-9, BBB disruption, and infarct size at 24 hours after transient MCAO compared with wild-type controls. Furthermore, the BBB disruption in MMP-9 null mice receiving wild-type bone marrow occurred as early as 1 hour after reperfusion. In contrast, wild-type animals with MMP-9 null bone marrow showed barely detectable levels of MMP-9 in the brain, with considerable attenuation in BBB disruption and brain infarct size. These findings show that MMP-9 from bone marrow-derived cells is an important factor involved in early BBB disruption after stroke. 67 (3) Depleting leukocytes can decrease the BBB disruption and the rate of HT within the first 24 hours of ischemic stroke. When neutrophils are depleted with vinblastine or anti-neutrophil antibody, endothelial disruption and the rate of HT are decreased in rodent stroke. 68, 69 Likewise, inhibiting neutrophils with a CD11b/CD18 antagonist decreases the degree of BBB disruption and tPA-related HT after MCAO in rats. 70 In contrast, when neutrophils are increased via lipopolysaccharide there is an increase in early BBB disruption in rodent stroke. 71 Neutrophils have been shown to be an important source of MMP-9 within the first 24 hours of ischemic stroke. In a rat MCAO stroke model, blocking neutrophil infiltration reduced MMP-9 in the brain. 72 In particular, two forms of MMP-9 that were present in neutrophils (a 95-kDa form, and MMP-9 dimers) were only present when neutrophil infiltration was not blocked. 72 In humans with ischemic stroke, MMP-9-positive neutrophil infiltration has also been associated with BBB breakdown, basal lamina type IV collagen degradation, and HT. 73 Thus, neutrophils appear to be an important source of early MMP-9 in ischemic stroke.
(4) The mechanism by which blood-derived MMP disrupts the BBB and leads to HT is not clear. Plasma MMP-9 may open the BBB from the luminal side of the vessel by acting directly on tight junction proteins (TJPs), or may be taken up into endothelial cells and act on the basal lamina. Alternatively, neutrophils that enter into brain could release MMP that acts directly on TJPs and/or basal lamina. 73 Matrix metalloproteinase actions on the basal lamina (e.g., collagen IV, fibronectin, and laminin) could disrupt the endothelial-pericyte-astrocyte complex and facilitate BBB injury and promote HT. 41 The role of TJPs in early HT is unclear since one study found intact TJPs at 24 hours after stroke 74 whereas a human study found increased blood levels of TJPs to be predictive of HT. 75 Early Hemorrhagic Transformation: Role of Other Leukocyte Factors Though leukocyte-derived MMPs appear to be one mediator of early HT, additional leukocyte-derived molecules have been implicated. 76 We examined mRNA expression in blood within 3 hours of ischemic stroke onset in humans before administration of tPA. Twenty-nine genes were differentially expressed in patients that developed HT. Six genes predicted HT in a second cohort with 80% sensitivity and 70% specificity. 76 These genes included amphiregulin, membrane-associated ring finger (C3HC4) 7, SMAD family member 4 (SMAD4), inositol polyphosphate-5phosphatase (INPP5D), multiple coagulation factor deficiency 2 (MCFD2), and vascular endothelial growth inhibitor (Figure 2) .
Amphiregulin enhances neutrophil migration across epithelial cell layers by altering E-cadherin tight junctions, promotes IL-8 release, and increases MMP-9 and vascular endothelial growth factor (VEGF) through MAP kinase pathways. 76 Thus, it may also promote HT. Multiple coagulation factor deficiency 2 was decreased in those who developed HT. It regulates transport of coagulation factors V and VIII from endoplasmic reticulum to the Golgi apparatus, and mutations of the gene result in a bleeding disorder. 76 Thus, low MCFD2 levels might predispose to HT. SMAD family member 4 was also elevated in blood leukocytes by 3 hours in those who later developed HT. 76 It is a target of transforming growth factor b (TGFb) and regulates N-cadherin expression in endothelial cells to stabilize the BBB. Mutations of SMAD4 cause hereditary hemorrhagic telangiectasia, and SMAD4-TGFb signaling is associated with extracellular matrix remodeling and formation of aortic dissections and aneurysms. 76 Two SMAD4 target genes were also elevated in our study: interleukin-1 receptorassociated kinase 3 (IRAK3) and INPP5D. The IRAK3 is involved in toll-like receptor signaling, mainly in monocytes, and INPP5D regulates proliferation and programming of myeloid cells. Our data suggest that TGFb signaling via SMAD4 and IRAK3/INPP5D in leukocytes within 3 hours of ischemic stroke may be associated with increased risk of HT after ischemic stroke (Figure 2 ). 76 In contrast, TGFb/SMAD2 signaling in a subset of monocytes that migrate into brain 1 to 7 days after stroke reduce the BBB disruption and the rate of HT (see section below titled Delayed Hemorrhagic Transformation: Role of Neuroinflammation). 77 Early Hemorrhagic Transformation: Role of Brain Metalloproteinases Though MMP from blood has a prominent role in early BBB disruption and HT, brain-derived proteases also contribute. The role of brain-derived proteases and brain-derived molecules develops over time after stroke, becoming a major contributor to BBB disruption and HT by 24 hours. This is discussed in greater detail in the section Delayed Hemorrhagic Transformation below. In early BBB disruption, brain MMP-2 and caveolin-1 have been implicated. 78, 79 Matrix metalloproteinase-2 has a key role in early BBB opening after ischemic stroke. 80 Brain MMP-2 is mostly derived from astrocytes, 81 endothelial cells, 82 and potentially leukocytes. It is increased in the brain within 1 to 3 hours of stroke onset in rats, mice, and primates and remains elevated for days. 57, 78, 79 Activators of MMP-2 including furin, thrombin, xanthine oxidase, and MT1-MMP are also increased early after stroke, providing further support to an increase in brain MMP-2 in cerebral ischemia. 40, 83 The rise in MMP-2 correlates with early opening of the BBB and degradation of the TJPs claudin-5 and occludin in rodent MCAO models. 78, 80, 84, 85 In addition, direct injection of MMP-2 into rodent brain disrupts the BBB and results in hemorrhage, further supporting a role of MMP-2 in early BBB disruption and HT in stroke. 84 Though MMP-2 is associated with early BBB disruption after stroke, its role in HT and effect on stroke outcome remains less clear. In primates, brain levels of MMP-2 were not significantly increased in animals with HT compared with those without. 86 In a 2-hour MCAO mouse model, an MMP-2 knockout failed to reduce the infarct size. 87 Though the MMP inhibitor (BB-1101) blocked MMP-2 increase in brain, a reduction in cerebral edema and BBB permeability was present only at 24 hours and not at 48 hours. 80 In contrast, a recent study of mice within 1 to 1.5 hours of MCAO found that MMP-2-deficient mice had a reduced rate of HT, smaller hemorrhage volume, and improved neurologic function compared with wild type. 79 The reasons for these differing results require further study to better understand the role of MMP-2 in acute stroke and early HT.
The membrane protein caveolin-1 (cav-1) has recently been shown to be involved in the early BBB disruption in ischemic stroke. Cav-1 may affect the BBB by inhibition of MMP activity and production of ROS. 88, 89 Indeed, infarct size is larger in cav-1 knockout mice. 88 After brain ischemia, cav-1 is decreased and correlates with an increase in brain MMP-2 and BBB permeability. 89 In cultured endothelial cells, inhibition of cav-1 with siRNA alters the distribution of the TJP claudin-5 in response to oxygen glucose deprivation. 78 Furthermore, in a 2-hour MCAO rat model microvessels have reduced occludin and redistribution of claudin-5. The authors suggest that after stroke cav-1 mediates changes in claudin-5, whereas MMP-2 mediates degradation of occludin. Thus, both MMP-2 and cav-1 may contribute to early BBB disruption after ischemic stroke.
DELAYED HEMORRHAGIC TRANSFORMATION
There is a persistent disruption of the BBB beginning by 1 day (18 to 24 hours depending on severity of ischemia) after ischemic stroke that can last for several weeks. 90, 91 This delayed and prolonged BBB opening is mediated predominantly by brainderived MMPs (MMP-9, MMP-2, and MMP-3), other brain proteases (plasmin, endogenous tPA, urokinase, and cathepsins), 41 neuroinflammation, as well as vascular remodeling and neovascularization. We propose that HT that occurs beyond 18 to 24 hours after ischemic stroke (delayed HT) occurs mostly due to the processes involved in delayed BBB opening after stroke (Figure 3 ). Indeed, early BBB disruption assessed at 2.5 to 3 hours after stroke does not predict delayed HT at 3 to 7 days. 92, 93 Delayed Hemorrhagic Transformation: Role of Brain-Derived Metalloproteinases At 18 to 24 hours after stroke, brain cells become an increasingly more important source of MMP-9 and MMP-3. 81, 86 Indeed, when neutrophils are depleted in a rat stroke model brain levels of MMP-9 or MMP-2 measured at 24 hours remain relatively unchanged compared with controls. 86 This suggests that the major source of MMP-9 and MMP-2 in the brain at 24 hours is not neutrophils, but brain. This finding is supported by Maier et al 65 who showed that the primary source of MMP-9 in the brain at 24 and 72 hours is not neutrophils but brain cells ( Figure 2 ). In addition, other proteases derived from brain cells also contribute to delayed HT, including MMP-10, MMP-13, MMP-14, TNF-a converting enzyme, plasmins (tPA and urokinase), and cathepsins. 32, 34, 38, 41, 56, 81 Several brain cells including astrocytes, neurons, microglia, and endothelium can express MMP-9 and have been found to be MMP-9 immunoreactive after stroke. The expression of MMP-9 may vary by severity of ischemia and time from stroke onset. Early after stroke (first 24 hours) MMP-9 is predominantly localized to endothelial cells. 94 However, as a stroke evolves beyond 24 hours to several days, MMP-9 is predominantly identified in brain cells including neurons, astrocytes, 94 and microglia. 81 This supports the notion that leukocytes, including neutrophils, contribute to MMP-9 early in stroke, whereas brain cells are the predominant source of MMP-9 later in stroke. Indeed, brain levels of MMP-9 correlate with delayed opening at 24 to 48 hours, 80 whereas plasma levels of MMP-9 at 3 hours are predictive of HT. [60] [61] [62] Matrix metalloproteinase-9 degrades TJPs (claudin-5, occludin, and ZO-1), and basal lamina proteins (fibronectin, lamin, and collagen). 85 After ischemic stroke, MMP-9 promotes BBB permeability, cerebral edema, and HT in animals and humans. 61, 85, 95 In mice deficient in MMP-9 or treated early with an MMP-9 inhibitor, there is a reduction in infarct size and degree of tight junction degradation. 55, 96, 97 Mechanisms for MMP-9 activation after ischemia include (1) ROS, 40 (2) TNF, IL-1, and other cytokines that activate MMP-3 which converts proMMP-9 into active MMP-9, 40 (3) actions of high-mobility-group-box-1 (HMGB1) on TLR4 receptors that then induce MMP-9, 98 or (4) NFkB induction of MMP-9 after ischemia.
Matrix metalloproteinase-2 has previously been discussed for its role in early HT as it is increased in brain within the first hours of stroke. However, MMP-2 in the brain remains persistently elevated for days. Thus, it likely contributes to both early and delayed HT.
Matrix metalloproteinase-3 is produced by pericytes 99 and endothelial cells 100 after ischemic stroke. It acts on proMMP-9 to produce active MMP-9 and thus may promote HT. 40 Indeed, MMP-3 has been associated with HT particularly when tPA is used. In postmortem human stroke brain MMP-3 is increased. 101 In mice brain MMP-3 mRNA and protein begins to rise within 24 hours of stroke onset. 100 The increase in MMP-3 may occur as a result of stroke-related inflammation or through induction by tPA. In mice, cerebral inflammation induced by lipopolysaccharide results in a breakdown of the BBB, an effect that is reduced in MMP-3 knockouts. 102 The MMP-3 activity is also promoted by tPA binding LRP and inducing the transcription factor NFkB. 103 In a mouse MCAO model, a knockout of MMP-3 reduced the rate of HT at 24 hours after tPA treatment. 100 In addition, a broad spectrum of MMP inhibitor (GM6001) did not further reduce the rate of HT in this MMP-3 knockout, suggesting that MMP-3 is an important metalloproteinase in HT.
Delayed Hemorrhagic Transformation: Role of Neuroinflammation
Inflammation after stroke is of increased interest as a mechanism of secondary brain damage and potentially a role in tissue repair. The role of inflammation in HT is an evolving area of study. Microglia are activated after stroke and have been shown to be an important source of MMP-9 that promotes BBB disruption and HT. 81 Peripheral monocyte interactions with endothelial cells induce MMP-9 expression, 104 and monocytes then enter brain and become macrophages also produce MMP-9. 81 Given monocyte infiltration into brain peaks over several days after stroke, they may contribute to delayed HT, though this needs further study.
Although monocytes may increase the MMP-9 after stroke, whether they promote HT remains unclear. In humans, augmentation of peripheral monocytes with granulocyte-macrophage colony-stimulating factor did not increase the rate of tPA-related HT. 105 Indeed certain subsets of monocytes may be beneficial after stroke. One study has shown a subset of peripheral monocytes can prevent delayed HT after ischemic stroke. 77 Within 24 hours of stroke onset, a subset of inflammatory monocytes (Ly6c hi , C-C chemokine receptor type 2 (CCR2 þ ), CX3CR1 þ ) infiltrate the infarct border via a CCR2-dependent pathway and differentiate into macrophages (Figure 2 ). 77 When these monocytes were depleted in a mouse stroke model, the rate of HT at both day 3 and day 7 increased. 77 In addition, when CCR2 was blocked there was an increase in delayed HT and worsening of neurologic function. Bleeding occurred around thin-walled, dilated neovessels in the infarct border zone and was accompanied by a decrease in TGFb1, collagen 4, and Smad2. Injection of TGFb1 into the infarct border reduced HT in monocyte-depleted mice. 77 These data suggest that a subset of peripheral monocytes recruited early via CCR2 into brain promote delayed repair of the neurovascular unit and prevent delayed HT 77 (Figure 2) .
In contrast, other studies have shown that inflammatory monocytes and the CCR2 pathway have harmful effects on the brain. 106 In mice deficient in CCR2, 30 minutes of MCAO results in reduced infarct size, decreased BBB permeability, and decreased infiltration of monocytes and neutrophils. 107 In humans, increased levels of the CD14 high CD16 À monocyte subtype (corresponds to mouse Ly6c high CCR2 þ ) are associated with worse outcome and early clinical deterioration, whereas increased levels of CD14 high CD16 þ are associated with reduced mortality. 108 Thus, certain monocyte subsets may contribute to BBB disruption/repair and HT after ischemic stroke, though additional study is needed.
Delayed Hemorrhagic Transformation: Role of Vascular
Remodeling Vascular remodeling and angiogenesis are an important component of recovery after stroke; however, they may also promote HT. For new vessels to be incorporated into existing vasculature, a number of growth factors, MMPs, and other molecules form new vessels and the neurovascular unit. During this vascular remodeling, vessels are leakier and prone to HT. 90 Vascular endothelial growth factor has an important role in vascular remodeling and angiogenesis. In rodent stroke, a reduction in VEGF through suppression of hypoxia inducible factor-1a results in a reduction in HT. 109 Likewise, inhibition of VEGF signaling reduces tPA-related HT. 110 In contrast, when VEGF is administered to a rodent within 1 to 24 hours of stroke the rate and severity of HT is increased. 111 Furthermore, VEGF administered 1 hour after stroke increases the BBB disruption, the rate of HT, and the size of infarction. 112 However, when VEGF is administered 3 to 21 after stroke, angiogenesis is enhanced with improved neurologic recovery, reduced BBB permeability, increased pericyte coverage of brain capillaries, and improved cerebral blood flow. 112, 113 Thus, VEGF has a biphasic role in stroke, with early VEGF promoting BBB disruption and HT, and later VEGF promoting BBB integrity and vascular function.
Matrix metalloproteinases also contribute to vascular remodeling and neovascularization. 40 Early and transient inhibition of MMPs after stroke reduces brain tissue injury, promotes new vessel formation at 3 weeks, and increases pericyte and endothelial expression of TJPs (ZO-1, occludin, and claudin-5). 99 In contrast, delayed treatment with MMP inhibitors 7 days after stroke suppresses neovascular remodeling, increases brain injury, and impairs functional recovery at 14 days. 94 Angiopoietins might also be involved in delayed HT. In rodent stroke, alteration of angiopoietin-1 in the ischemic core mediates BBB disruption whereas angiopoietin-2 regulates neovascularization. 114 In stroke patients, increased blood levels of angiopoietin-1 are associated with tPA-related hemorrhage. 115 High-mobility-group-box-1 is also involved in neurovascular repair after ischemic stroke. It is a damage-associated molecularpattern molecule that is released by perivascular astrocytes after ischemic stroke. It acts on the HMGB1 receptor on endothelial progenitor cells (EPCs) to promote peri-infarct angiogenesis (Figure 2 ). 116 The effect of HMGB1 on EPC has been shown to improve long-term behavioral outcome after stroke, though any effects on HT have not been studied.
Delayed Hemorrhagic Transformation: Role of Reactive Oxygen Species
Reactive oxygen species have an important role in vascular remodeling and angiogenesis, 117 and thus likely contribute to delayed HT. They have regulatory effects on many angiogenic factors including VEGF, hypoxia inducible factor-1a signaling, MMP activation, NFkB activity, protein kinase C activity, ERK1/2 activity, and p38 MAP kinase activity. 118 They can act as signaling molecules to regulate cell growth, differentiation, and angiogenesis. 119 When endothelial cells are exposed to ROS, angiogenic patterns are induced including cell proliferation, migration, and tube formation. 117 ROS also promote EPC mobilization, differentiation, and homing and thus contribute to vascular remodeling and angiogenesis. 119 NADPH oxidase (NOX) is an important source of superoxide and ROS. NOX4-induced ROS has been shown to promote endothelial cell migration and proliferation as well as promote blood flow recovery after ischemia. 117 When NOX1 is knocked out in a mouse, angiogenic activity is impaired. 120 Likewise, in the NOX2 mouse knockout or when NOX2 is inhibited, ischemia-induced neovascularization is impaired. 119 Though ROS are known to have an important role in ischemic angiogenesis, additional study is required to more specifically determine the role of ROS in delayed HT after ischemic stroke.
Delayed Hemorrhagic Transformation: The Role of Src Family Kinases
After HT of ischemic stroke, blood products such as thrombin are released into the brain and promote further damage of ischemic tissue. To study this injury, thrombin was injected into the ventricle of adult rats. 121 This resulted in vascular leakage of Evans Blue at 24 hours and increased brain water content at 24 hours. We postulated that thrombin acted on protease activated receptors, which activated Src family kinase (SFK) family members to phosphorylate and activate NMDA receptors to kill neurons, and to phosphorylate MMPs, VEGF, and other factors to open the BBB ( Figure 5A ). Indeed, the SFK inhibitor PP2 prevented BBB breakdown and brain edema produced by ventricular thrombin. 121 Since this BBB breakdown and brain edema resolved by 14 days after thrombin, we further postulated that SFK phosphorylation of cell-cycle genes would lead to BBB repair. Indeed, new endothelial cells and new perivascular astrocytes are born at 7 days and 14 days after intraventricular thrombin ( Figures  5B to 5E ). 121 Furthermore, administration of PP2 (an SFK inhibitor) from days 2 to 6 after intraventricular thrombin prevented the repair in the BBB as manifested by persisting Evans Blue leakage and persisting brain edema. 121 Thus, Src kinase family members mediate acute BBB injury produced by thrombin, but also mediate chronic BBB repair. 121 Additional study of thrombin and blood products that induced BBB disruption and tissue injury after stroke may identify novel targets to reduce the effects of HT.
TREATMENT OF HEMORRHAGIC TRANSFORMATION
Several therapies have been evaluated for the prevention and treatment of HT. Though many compounds have been shown to decrease HT in animals, 122 to date none have successfully been translated to humans. Targets that have been evaluated include reducing ROS, inhibiting MMPs, and modulating targets that affect BBB permeability.
Early administration of MMP inhibitors reduces BBB permeability and the rate of HT. MMP-9 and MMP-3 inhibitors decrease HT produced by tPA. 123 Batimastat (BB-94) is a board spectrum MMP inhibitor that reduces tPA-related HT in rats. Minocycline inhibits MMP-9 and microglia and reduces tPA-related HT in rats. 124 Ongoing studies are evaluating the role of minocycline to reduce HT in stroke patients. 125 Though early inhibition of MMP-9 can reduce HT in animals, delayed or persisting MMP inhibition is known to enhance brain injury and worsen stroke outcome. 94 Several therapies have targeted ROS to reduce HT. Though initial studies of the spin-trap-agent NXY-059 showed promise to reduce HT in animals, 51 it failed to reduce HT in patients with stroke. 53 Another spin trap agent, N-t-Butyl-Phenylnitrone (PBN), also reduced tPA-related HT in rodent stroke. 52 However, when used in a rabbit clot embolic model, PBN worsened HT. 126 Edaravone is a free radical scavenger that can reduce HT in rat stroke. 127 However, in patients with cardioembolic stroke edaravone was found to increase the rate of HT. 128 Isoflurane may increase ROS by inhibiting superoxide dismutase and catalase. It has been found to increase HT in rats with focal ischemia. 129 Hydrogen gas may reduce oxidative stress in the brain and has been found to reduce hyperglycemia-enhanced HT in a rat stroke model. 130 Other agents that also attenuate tPA-related HT include activated protein C, PDGFRa antagonists, cilostazol (a phosphodiesterase inhibitor), 131 melatonin, fasudil (rho kinase inhibitor), fingolimod (sphingosine 1-phosphate receptor agonist), 132 poly ADP ribose polymerase (PARP) inhibitors, 133 sulfonylurea receptor 1 (Sur1) inhibitors (glyburide), 134 17-beta estradiol, FK506 (tacrolimus), 135 VEGF inhibition, 110 and hyperbaric oxygen. 136 In contrast, erythropoietin exacerbates tPA-related HT. 137 The reasons that several promising therapies in animals have failed to translate to successful therapies for HT in human stroke remain unclear. It highlights that animal studies may not predict pharmacological effectiveness in human HT and supports the use of several different animal models to evaluate treatments to prevent HT. 138 We suggest consideration be given to the different mechanisms and subtypes of HT. Though a therapy may decrease tPA-related HT, this does not necessarily indicate a benefit in HT related to reperfusion without tPA. Thus, experimental studies designed to treat all types of HT might include tPA-related HT and reperfusion induced HT without tPA. Furthermore, HT that occurs early may require a different therapeutic approach than delayed HT. Many of the small animal studies to date have focused on early HT. A therapy that can show effectiveness both in models of early HT and in models of delayed HT may be more likely to translate to the clinic. 51, 138 The spontaneously hypertensive rat (SHR) may be a good model of delayed HT, as a 0.5-hour MCAO has been found to produce HT beyond 24 hours in 75% of animals and 450% of the HTs occur after 48 hours 139 ( Figure 1B) . Another model of delayed HT is an MCAO in a mouse with depleted monocytes or selective CCR2 inhibition, as this has been found to have increased HT on days 3 and 7 after ischemic stroke. 77 
CLINICAL FACTORS ASSOCIATED WITH HEMORRHAGIC TRANSFORMATION
A number of clinical factors have been associated with HT in patients with stroke. Stroke severity and infarct size is the single factor that best correlates with HT. 1 Other factors include increasing age, baseline systolic blood pressure, hypertension, serum glucose, and antiplatelet use. A meta-analysis of 55 human studies reported factors associated with tPA-related HT including older age, greater stroke severity, higher glucose, atrial fibrillation, congestive heart failure, renal impairment, previous antiplatelet agents, leukoaraiosis, and a visible acute cerebral ischemic lesion on pretreatment brain imaging. 50 These findings are consistent with animal stroke models that have found increasing age, hypertension, and blood glucose predispose to HT. [140] [141] [142] Clinical Factors: Age, Hypertension, Hyperglycemia, and Hemorrhagic Transformation Increasing age has frequently been associated with an increased risk of HT in patients with stroke. 8, 26, 50, [143] [144] [145] [146] [147] [148] The mechanisms by which age may contribute to HT are unclear. Age may enhance the production of ROS which promotes BBB disruption. An increase in BBB permeability has been observed with age. 149 Age may also be linked to changes in the cerebral vasculature that promote HT such as a reduction in collateral circulation or increase in arterial disease. 150 Though age is associated with an increased risk of HT, treatment with tPA has been shown to improve outcomes in stroke patients 480 years of age. 151 Hypertension is also associated with an increased risk of HT in stroke patients. 8, [144] [145] [146] 152, 153 Acute elevations in blood pressure are presumed to directly affect BBB permeability and increase HT.
In a rabbit clot model acute hypertension promotes tPA-related HT, 154 whereas decreasing prestroke blood pressure in rats reduces HT. 155 In patients increased blood pressure after tPA treatment is associated with HT. 152 The risk of HT increases with each 10 mm Hg rise in systolic blood pressure from 140 to 180 mm Hg. 153 Furthermore, reducing blood pressure to below 185/110 mm Hg before administration of tPA is part of the treatment guidelines to reduce the risk of HT. 156 The effects of chronic hypertension on cerebral circulation may also increase the risk of HT. Chronic hypertension alters the vasculature, increasing vascular resistance, reducing vascular compliance, and impairing collateral circulation. 157 Indeed, in the SHR infarcts tend to be larger, with increased BBB disruption and increased rates of HT compared with normotensive Wistar rats. 52, 139 Hypertension may also enhance formation of ROS, activation of MMPs, and inflammation and thus potentially promote BBB disruption and HT. 158 An interaction between age and hypertension may also exist. In a SHR stroke model, the rate of HT was the same in young rats compared with aged rats. However, in normotensive rats age did increase the rate of HT. 140 Increased serum glucose is associated with an increase risk of HT in stroke patients. In transient MCAO rat models, acute hyperglycemia increases BBB disruption and the rate of HT. 141, 142 Hyperglycemia also increases HT in a cat stroke model. 159 How hyperglycemia enhances HT remains unclear. It may promote ROS production, MMP activity, and proinflammatory cytokine expression. 141, 159 Elevated glucose may also enhance the severity of ischemic injury through effects on the vasculature, and thus contribute to HT. 160 Whether lowering glucose in patients with acute stroke can reduce the rate of HT remains unclear, though insight may be provided by an ongoing clinical trial. 161 Clinical Factors: The Coagulation System and Hemorrhagic Transformation The coagulation system also contributes to HT. Use of anticoagulants, antiplatelets, and thrombolytics, as well as an elevation in clotting times, reduction in platelets, and abnormalities in clotting factors have been associated with an increased risk of HT. Altered hemostasis may increase the probability of HT when the BBB is disrupted and may worsen HT by transforming smaller petechial hemorrhages into a larger parenchymal hemorrhage.
Anticoagulants have been shown to increase the risk of HT, and an international normalized ratio of 41.7 is a contraindication to tPA use in patients as a result of this increased risk. 156 In rats, anticoagulation increases the risk of HT in both tPA-treated anduntreated stroke. 162 After stroke onset, early initiation of anticoagulants, heparin or enoxaparin increases the risk of HT. 163 The activated partial thromboplastin time is associated with HT, 156, 164 and genetic mutations in coagulation factors (factor XII and factor XIII) have been associated with HT. 164, 165 A mutation in collagen type IV, an important component of the BBB basal lamina, promotes cerebral hemorrhage related to anticoagulants. 166 In ischemic stroke, collagen type IV is reduced in the basal lamina within the first 1 to 24 hours, thus it may contribute to coagulationrelated HT. 12, 42 Antiplatelet agents also increase the risk of HT in patients. 8, 50, 144, [167] [168] [169] Antiplatelet use before tPA treatment or antiplatelet use within the first 24 hours of tPA treatment increases the risk of tPA-related HT. 8, 156 In addition, dual antiplatelet therapy also increased the risk of HT after stroke. 167 Antiplatelet use has been included in some of the clinical HT risk scores (Table 1) . A low platelet count is predictive of HT, 143 and levels below o100 000/ mm 3 are a contraindication to tPA because of increased HT risk. 156 Tissue plasminogen activator is a serine protease that degrades fibrin-based blood clots by generating plasmin from plasminogen. As previously discussed, tPA increases the risk of HT through several mechanisms including increased reperfusion, activation of MMPs, and receptor signaling through LRP and PDGFRa. Other thrombolytics such as streptokinase and tenecteplase also promote HT. 25 
Clinical Factors: Prediction of Hemorrhagic Transformation in Ischemic Stroke Patients
To improve the safety of tPA and potentially extend its therapeutic window, clinical factors, imaging parameters, and blood biomarkers have been evaluated as predictors to identify patients at risk for tPA-related HT.
Clinical scores to predict HT that have been developed include the Multicenter Stroke Survey, 143 the Hemorrhage After Thrombolysis score, 170 and the Safe Implementation of Thrombolysis in Stroke Symptomatic Intracerebral Hemorrhage score, 144 the blood Sugar, Early infarct signs and hyperDense cerebral artery sign, Age, and NIHSS score, 145 the Glucose Race Age Sex Pressure Stroke Severity score, 146 the Stroke Prognostication using Age and NIHSS-100 index, 147 and the iScore 148 (Table 1 ). Though each score is able to identify patients at increased risk of HT, they do not achieve sufficient sensitivity or specificity to withhold tPA in otherwise tPA eligible patients. 171 Thus, additional predictors to stratify risk of HT after ischemic stroke have been sought, including neuroimaging and blood biomarkers.
Several brain imaging approaches have been evaluated to predict HT after stroke (Table 1 ). In one study, magnetic resonance imaging (MRI) enhancement patterns were associated with HT. 172 In another, the presence of gadolinium enhancement of cerebrospinal fluid termed Hyperintense Acute Reperfusion Marker was found to be an independent predictor of HT. 173 Blood-brain barrier permeability assessed by perfusion CT is also predictive HT. 174 Other MRI measures that predict HT include T2*permeability MRI, 175 apparent diffusion coefficient, 176 and very low cerebral blood volume. 177 Collateral circulation has also been associated with HT in patients with stroke. After vessel occlusion, leptomeningeal collaterals can maintain cerebral blood flow to distal brain tissue. 150 In patients, the extent and rate of pial artery backfilling has been used as an indirect assessment of collateral circulation. Poor collaterals are associated with larger infarction and worse functional outcome at 3 months. 178 Furthermore, poor collaterals are a predictor of HT in patients where recanalization occurs. In a study of 105 stroke patients, HT occurred more frequently in those with poor pial collaterals (25%, 8/32) compared with those with good pial collaterals (2.8%, 2/72) (P ¼ 0.0004). 179 In a study of 222 endovascular-treated stroke patients, symptomatic HT was more common in patients that recanalized and had poor collaterals (30.2%) compared with patients that recanalized and had good collaterals (14.3%). This highlights that reperfusion of infarcted brain tissue is a critical factor in HT, and poor collaterals likely increase the size and severity of cerebral infarction and thus promote HT.
Blood biomarkers may have utility to identify ischemic stroke patients at risk for HT. Patients at increased risk for HT might have their tPA therapy modified or be administered a drug to prevent HT. Blood biomarkers that have been associated with HT in ischemic stroke include MMP-9, 60,61,122 cellular fibronectin, 62 fibrinogen, 180 S100B, 181 ferritin, 182 activated protein C, 183 thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 184 (Table 1 ). Other molecules that predict HT include: Vascular Adhesion Protein-1, 185 a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils; serum levels of TJPs (CLDN5, OCLN, and CLDN5/ZO1 ratio); 75 and PDGF-CC isoforms, 37 which is activated by tPA and acts on astrocyte PDGFRa (Figure 2) .
A few genetic factors have been associated with tPA-related HT. Single-nucleotide polymorphisms in a-2-macroglobulin, Factor XII 164 and Factor XIII 165 have each been associated with HT. Several RNA expressed in circulating leukocytes within 3 hours of ischemic stroke are also associated with HT and can predict tPArelated HT with 485% accuracy 76 (Figure 2) .
The above review summarizes HT after ischemic stroke in animals and humans. Though major progress has been made, this has yet to translate to the clinic and alter practice. Well-designed clinical trials are needed to advance the basic and clinical science of HT to clinical care. Ideally, agents evaluated in clinical trials will target a specific type of HT, or potentially be those therapies that demonstrate effectiveness in animal models of both early and delayed HT produced with and without tPA.
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